Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
387.6 USD | -3.60% | -2.58% | +26.45% |
May. 08 | Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing | MT |
May. 03 | Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.57 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.45% | 11.98B | C+ | ||
+22.56% | 46.71B | B- | ||
-1.51% | 41.52B | B | ||
+48.83% | 41.8B | A | ||
-3.42% | 29.55B | C | ||
+10.13% | 25.78B | B- | ||
-20.44% | 19.26B | B | ||
-0.14% | 12.14B | B+ | ||
-0.47% | 12.08B | C+ | ||
+18.74% | 11.58B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEDP Stock
- Ratings Medpace Holdings, Inc.